Document Detail


Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?
MedLine Citation:
PMID:  22212573     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Boceprevir and telaprevir are the first two protease inhibitors available for the treatment of patients infected with hepatitis C virus (HCV) genotype 1. A sustained virological response (SVR) of 70-80% is observed when either of these protease inhibitors is utilized with pegylated interferon (PEG-IFN) and ribavirin (RBV) in treatment naïve patients. Both agents are also highly effective in patients who failed to achieve a SVR during previous treatment with PEG-IFN/RBV. A rapid virological response (RVR) is observed in 56-60% of treatment naïve patients. Patients who achieve a RVR can be treated with a shorter course of therapy (24-28 weeks) and still achieve a SVR rate of 90% or higher. Patients who do not achieve a RVR, those with cirrhosis and certain prior non-responders should be treated for 48 weeks. Although the SVR rates observed with boceprevir and telaprevir are quite similar both globally and within sub-populations, the treatment algorithms for the two agents are unique. The decision of which protease inhibitor to use should assess several factors including the treatment scheme, duration of therapy, adverse event profile, cost and the likelihood of achieving a RVR. The latter is highly dependent upon IFN sensitivity and the IL28B genotype.
Authors:
Mitchell L Shiffman; Rafael Esteban
Related Documents :
24259523 - Longitudinal analysis of distribution and function of plasmacytoid dendritic cells in p...
24257463 - Sickle cell disease and hiv: a case highlighting management challenges for children in ...
24259523 - Longitudinal analysis of distribution and function of plasmacytoid dendritic cells in p...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Liver international : official journal of the International Association for the Study of the Liver     Volume:  32 Suppl 1     ISSN:  1478-3231     ISO Abbreviation:  Liver Int.     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-01-03     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101160857     Medline TA:  Liver Int     Country:  England    
Other Details:
Languages:  eng     Pagination:  54-60     Citation Subset:  IM    
Copyright Information:
© 2012 John Wiley & Sons A/S.
Affiliation:
Liver Institute of Virginia, Bon Secours Health System, Richmond and Newport News, VA, USA; Department of Medicine, Eastern Virginia Medical School, Norfolk, VA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Triple therapy with boceprevir for HCV genotype 1 infection: phase III results in relapsers and nonr...
Next Document:  Triple combination treatment for chronic hepatitis C with Protease Inhibitors, pegylated interferon ...